ImmunityBio Achieves Landmark Success with Anktiva
ImmunityBio, a leader in innovative cancer therapies, experienced a groundbreaking year in 2025, with its flagship treatment, Anktiva, making waves across the globe. The biotechnology company announced a staggering 700% rise in revenue for Anktiva, skyrocketing from $15 million in 2024 to $113 million in 2025. This remarkable growth validates the potential of immunotherapy in addressing severe cancer cases.
Saudi Approvals Lead Expansion
In a pivotal move, the Saudi Food and Drug Authority (FDA) approved Anktiva for two critical indications: metastatic non-small cell lung cancer and BCG-unresponsive bladder cancer. This approval marks a global milestone as it fortifies ImmunityBio’s foothold in international markets. The geographical expansion further aligns with their strategy of tapping into underserved areas with high demands for advanced cancer treatments.
With prior approvals in the U.S., U.K., and conditional EU consent, Anktiva is now poised to make an even bigger impact globally. Considered revolutionary, Anktiva leverages IL-15 to stimulate T cells and natural killer cells, driving effective responses in cancer patients.
Unprecedented Growth in Unit Sales
A key driver of this growth has been the 750% increase in unit sales over the past year. The company’s efforts in promoting physician adoption and delivering superior patient outcomes have been highly effective. The rising confidence of healthcare professionals in immunotherapy speaks volumes about Anktiva’s reliability and transformative impact on cancer treatment paradigms.
This surge in adoption is complemented by ImmunityBio’s success in ramping up clinical trials. The Phase 2b trial for BCG-naïve bladder cancer is progressing ahead of schedule, with full patient enrollment targeted for the first half of 2026.
Strong Financial Projections and Analyst Ratings
Fourth-quarter revenues reached $38.3 million, representing a 20% sequential increase and 431% year-over-year growth. Analysts have taken note of ImmunityBio’s momentum, maintaining Strong Buy ratings with an average price target of $7.33, projecting an 85.57% upside. The company’s 80.41% gross margin further solidifies its financial sustainability.
For investors and biotech enthusiasts, the strong financial forecasts, approvals, and clinical advancements make ImmunityBio a top consideration. Its $3.9 billion market cap and its potential to achieve label expansions in 2026 further amplify its growth story.
Invest in Better Health Outcomes
The innovations achieved by ImmunityBio are a testament to the rapid advancements in oncology. As cancer treatment evolves, immunotherapy is redefining patient outcomes in unprecedented ways. Interested in advanced oncology care? Check out Roche’s cutting-edge cancer treatments.